Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P54278: Variant p.Thr597Ser

Mismatch repair endonuclease PMS2
Gene: PMS2
Feedback?
Variant information Variant position: help 597 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LB/B The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Threonine (T) to Serine (S) at position 597 (T597S, p.Thr597Ser). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and polar (T) to small size and polar (S) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help Normal DNA mismatch repair activity; significantly reduced interaction with MLH1. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 597 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 862 The length of the canonical sequence.
Location on the sequence: help KRFKKEEILSSSDICQKLVN T QDMSASQVDVAVKINKKVVP The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         KRFKKEEILSSSDICQKLVNTQDMSASQVDVAVKINKKVVP

Mouse                         KRFKTEERPSNVNISQRLPGPQSTSAAEVDVAIKMNKRIVL

Chicken                       RRFKNEADDFKAGIHPKVENTRNYMPC-VDVLVEVKKKTVP

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 862 Mismatch repair endonuclease PMS2
Modified residue 597 – 597 Phosphothreonine
Alternative sequence 184 – 862 Missing. In isoform 4.
Alternative sequence 269 – 669 Missing. In isoform 2.
Alternative sequence 573 – 862 Missing. In isoform 3.
Mutagenesis 577 – 577 K -> N. Affects binding to importins alpha, including KPNA2, hence may affect import to the nucleus.
Mutagenesis 578 – 578 R -> N. Affects binding to importins alpha, including KPNA2, hence may affect import to the nucleus.



Literature citations
Prevalence of germline mutations of hMLH1, hMSH2, hPMS1, hPMS2, and hMSH6 genes in 75 French kindreds with nonpolyposis colorectal cancer.
Wang Q.; Lasset C.; Desseigne F.; Saurin J.-C.; Maugard C.; Navarro C.; Ruano E.; Descos L.; Trillet-Lenoir V.; Bosset J.-F.; Puisieux A.;
Hum. Genet. 105:79-85(1999)
Cited for: VARIANTS LYNCH4 GLN-479 AND ILE-622; VARIANTS LYS-485; ALA-511 AND SER-597; Polymorphisms and HNPCC: PMS2-MLH1 protein interactions diminished by single nucleotide polymorphisms.
Yuan Z.Q.; Gottlieb B.; Beitel L.K.; Wong N.; Gordon P.H.; Wang Q.; Puisieux A.; Foulkes W.D.; Trifiro M.;
Hum. Mutat. 19:108-113(2002)
Cited for: CHARACTERIZATION OF VARIANT LYNCH4 ILE-622; CHARACTERIZATION OF VARIANT SER-597; Heterozygous mutations in PMS2 cause hereditary nonpolyposis colorectal carcinoma (Lynch syndrome).
Hendriks Y.M.; Jagmohan-Changur S.; van der Klift H.M.; Morreau H.; van Puijenbroek M.; Tops C.; van Os T.; Wagner A.; Ausems M.G.; Gomez E.; Breuning M.H.; Broecker-Vriends A.H.; Vasen H.F.; Wijnen J.T.;
Gastroenterology 130:312-322(2006)
Cited for: VARIANTS LYNCH4 ILE-585 AND ILE-622; VARIANTS VAL-18; GLN-20; SER-470; LYS-485; GLU-541; SER-597 AND ALA-857; Inactivation of DNA mismatch repair by variants of uncertain significance in the PMS2 gene.
Drost M.; Koppejan H.; de Wind N.;
Hum. Mutat. 34:1477-1480(2013)
Cited for: CHARACTERIZATION OF VARIANTS VAL-18; GLN-20; ALA-41; GLU-60; THR-423; LYS-485; ALA-511; MET-511; GLU-541; LEU-563; ILE-571; SER-597 AND ALA-857; CHARACTERIZATION OF VARIANTS LYNCH4 ASN-46; ILE-46; PRO-205; GLU-207; VAL-263; GLN-479; ILE-622; ALA-663; LYS-705; ASP-750; ARG-797 AND TYR-843; MUTAGENESIS OF GLU-41 AND TYR-519; Refining the role of PMS2 in Lynch syndrome: germline mutational analysis improved by comprehensive assessment of variants.
Borras E.; Pineda M.; Cadinanos J.; Del Valle J.; Brieger A.; Hinrichsen I.; Cabanillas R.; Navarro M.; Brunet J.; Sanjuan X.; Musulen E.; van der Klift H.; Lazaro C.; Plotz G.; Blanco I.; Capella G.;
J. Med. Genet. 50:552-563(2013)
Cited for: VARIANT LYNCH4 ILE-46; VARIANTS GLN-20; SER-470; SER-597 AND SER-775; CHARACTERIZATION OF VARIANT LYNCH4 ILE-46; CHARACTERIZATION OF VARIANTS GLN-20 AND SER-470; MUTAGENESIS OF ASP-70; FUNCTION; SUBCELLULAR LOCATION;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.